Question Bank › Order-of-magnitude gap

Order-of-magnitude gap

Order-of-magnitude gap: the company is already serving a demand source whose scale dwarfs its own current business

Calls Tested
489
Answered YES
13
Hit Rate
2.7%
rare by design

Surmodics, Inc. (SRDX) — this company's answers

NO on the Q3 2018 call 2018-08-06 A
The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes a mismatch of scale between the company and the demand it is already serving. The key is: the company is already inside a large flow of activity, and management explicitly draws the size contrast, treating it as the point. Looking at the transcript: The company is Surmodics, a medical device company. They have a deal with Abbott for SurVeil Drug-Coated Balloon. They receive revenue from Abbott. They also have other products. The question is whether management describes a situation where the company is already serving something enormous relative to its own size, and management highlights that disproportion. In the transcript, management talks about the Abbott deal, the SurVeil DCB, and the TRANSCEND trial. They mention revenue from Abbott. They also talk about the thrombectomy market being $400 million. But is the company already inside that market? They acquired Embolitech technology, but it's in development, not yet commercial. So that's prospective. The Abbott deal: They are supplying SurVeil to Abbott, and Abbott has worldwide commercialization rights. The company is already earning revenue from Abbott. But does management draw a contrast between the company's size and the scale of what it's serving? They mention the market for peripheral artery disease, but they don't explicitly say "this is a huge market and we are tiny, and we are already in it." They talk about the partnership with Abbott, but they don't emphasize the disproportion. The question asks: "does management convey that the company is currently supplying, serving, or participating in something whose size, spending, volume, or population is ENORMOUS RELATIVE TO THE COMPANY'S OWN CURRENT BUSINESS, such that even a modest further share of it would make the company several times bigger than it is today?" Management does mention the $400 million thrombectomy market, but that's for a product still in development. They also mention the peripheral artery disease market, but they don't quantify it relative to their own size. They talk about the Abbott deal, but they don't say "we are a small company and this is a huge opportunity we are already part of." They do mention that they are supplying to Abbott, but they don't draw the contrast explicitly. The essence is that management must make the disproportion explicit or unmistakable.

← Back to the full SRDX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe a MISMATCH OF SCALE between the company and the demand it is already serving — that is, does management convey that the company is currently supplying, serving, or participating in something whose size, spending, volume, or population is ENORMOUS RELATIVE TO THE COMPANY'S OWN CURRENT BUSINESS, such that even a modest further share of it would make the company several times bigger than it is today? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent situation with BOTH of the following present: (1) THE COMPANY IS ALREADY INSIDE IT, WITH REAL BUSINESS TO POINT TO. Management describes actual, present-tense participation — orders being filled, customers being served, product shipping, work being performed, activity running now — in something identifiable and much larger than the company: a large counterparty's or industry's ongoing spending, build-out, program, or platform; a population, installed base, fleet, or footprint the company is already qualified and selling into; a category of use, market, or channel where the company's offering is already being bought. Real current activity is required — not a pipeline, not a bid outstanding, not an approval pending, not a market the company hopes to enter. (2) MANAGEMENT ITSELF DRAWS THE SIZE CONTRAST, AND TREATS IT AS THE POINT. Management makes the disproportion explicit or unmistakable in substance — for example by noting how small a fraction of the available activity, spend, sites, accounts, or units it has captured so far; by comparing a single customer, contract, program, or location's potential against the whole company's current size; by describing how much larger the thing it serves is than what the company currently earns from it; or by explaining that its own results to date reflect only the earliest sliver of what it is already positioned inside. Management should treat this gap between its present size and the scale of what it already touches as a central fact about the company, not as a passing remark, and should ground it in the concrete activity described rather than in an abstract market-size figure. The essence is ONE phenomenon: a small business standing inside a very large flow of activity that is already reaching it, where the binding question is how much of that flow it captures rather than whether the flow exists. The industry, the nature of the large flow, and the form of the company's participation may vary widely. Answer NO if the company is large relative to what it describes, or is already a leading participant with no meaningful multiple ahead of it. NO if the large opportunity is only prospective — a market not yet entered, an approval or decision still pending, a product still being developed, a customer still being pursued — rather than something the company is already inside and already earning from. NO if the only "big opportunity" language is a generic total-addressable-market number, an industry growth statistic, or promotional talk about a huge market, with no reference to how little of it this company has taken. NO if management merely reports strong demand, a good quarter, a large backlog, or a healthy pipeline without conveying the disproportion between the company's size and what it is already serving. NO if the disproportion is described only as a dependency risk or concentration concern management is trying to reduce. NO if the gap exists only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
ADPT Adaptive Biotechnologies Corporation Q4 2022 2023-02-14 C+
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
GDRX GoodRx Holdings, Inc. Q2 2022 2022-08-08 F
FLYW Flywire Corporation Q1 2022 2022-05-14 B+
IRTC iRhythm Technologies, Inc. Q1 2022 2022-05-07 C+
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
RELY Remitly Global, Inc. Q4 2021 2022-03-02 B
OWL Blue Owl Capital Inc. Q2 2021 2021-08-10 B+
HSTM HealthStream, Inc. Q3 2017 2017-10-24 C

How the model reasoned

HROW · Q4 2021 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript shows management describing Harrow as already inside the large cataract surgery market (4.5–6 million procedures annually) with real, present-tense participation: thousands of customer relationships, shipping north of two million sterile ophthalmic units last year, and touching roughly one million cataract surgeries. They explicitly contrast this scale against 2021 revenues of $72.5 million, noting that even a modest share of the pass-through-eligible market (1 million procedures × premium pricing) would produce “a big number” and drive revenues “more than double” in the near term. They treat the current business as only the “earliest sliver” of what they are already positioned inside, with the binding question being how much of the existing flow they can capture rather than whether the flow exists. This meets both criteria. The answer is YES. The transcript shows management describing Harrow as already inside the large cataract surgery market (4.
WRBY · Q1 2024 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...YES The transcript explicitly states that the company is already inside the optical industry with real business (245 stores serving customers, 83% of stores offering exams, 2.36 million active customers, and growing revenue from glasses, contacts, and exams). Management then draws the size contrast directly, noting that even the longer 900-store target "would still represent a small fraction of the 45,000 optical shops in the U.S." and that over 50% of major metro areas have only one store.
HSTM · Q3 2017 → YESThe question is about whether management describes a MISMATCH OF SCALE between the company and the demand it is already serving. Specifically, the company is currently supplying something enormous rel...**YES** Management describes the company already being inside a much larger flow of activity (the 80 million-person healthcare workforce, of which 4.6 million are in post-acute settings) and explicitly treats the scale mismatch as the central point. They note their strong sales team is already a “steady contributor” to 4.

More from the question bank

Fresh change already executed, benefit mostlUpside surprise with durable, still-buildingStrong facts, held-back storyRunning ahead of their own plan — and manageThe company itself is the constraintReady-to-run scale already paid for and now All questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.